Nycomed extends GPO deal to Novation

Article

Nycomed Amersham Imaging of Princeton, NJ, has extended its contrast agent supply relationships with group purchasing organizations VHA and University HealthSystem Consortium (UHC) to Novation, the new company formed to supply the GPOs. The extension

Nycomed Amersham Imaging of Princeton, NJ, has extended its contrast agent supply relationships with group purchasing organizations VHA and University HealthSystem Consortium (UHC) to Novation, the new company formed to supply the GPOs. The extension also incorporates new Nycomed contrast agents not covered in the previous deals, such as the company’s Teslascan MRI liver imaging agent.

Nycomed Amersham previously had separate contrast supply deals with VHA of Irving, TX, and UHC of Oak Brook, IL. Those GPOs in January spun off their supply and purchasing organizations to form Novation, so Nycomed Amersham began negotiating a supply deal with the new entity.

The new agreement covers contrast agent purchasing for the next five years, beginning in January. It also includes provisions that should increase compliance among VHA and UHC members, according to a Nycomed Amersham spokesperson.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.